I'm LongbridgeAI, I can summarize articles.CLSA published a research report stating that the fundamentals of China's biopharmaceutical sector heading into 2027 are stronger than market sentiment suggests, with ongoing clinical validation, improving earnings delivery and strong out-licensing activities contrasting with weak liquidity and valuations.
The broker expected key regulatory and clinical milestones to drive the next round of sector catalysts, while demand from multinational pharmaceutical companies for original Chinese innovation is likely to remain strong. Its top picks are INNOVENT BIO (01801.HK) -2.100 (-2.448%) Short selling $109.73M; Ratio 28.183% and SKB BIO (06990.HK) -11.000 (-2.532%) Short selling $30.03M; Ratio 19.351% , both rated Outperform, with TP at HKD152 and HKD626.4 respectively.
The broker said it remains positive on China's biopharmaceutical sector due to solid fundamentals, reasonable valuations, and catalysts from clinical, regulatory and business development progress. It is optimistic about INNOVENT BIO's leading commercialization execution, diversified pipeline and proven global innovation capabilities, and also favors the global franchise potential of SKB BIO's sac-TMT and its multi-year earnings growth outlook.(sl/j)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-18 12:25.)
